Wall Street brokerages expect that Zafgen, Inc. (NASDAQ:ZFGN) will announce earnings per share of ($0.59) for the current quarter, Zacks reports. Zero analysts have issued estimates for Zafgen’s earnings. Zafgen posted earnings per share of ($0.38) during the same quarter last year, which indicates a negative year-over-year growth rate of 55.3%. The company is expected to announce its next quarterly earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Zafgen will report full-year earnings of ($2.02) per share for the current year. For the next fiscal year, analysts anticipate that the company will post earnings of ($1.35) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Zafgen.

Zafgen (NASDAQ:ZFGN) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.12.

A number of analysts have issued reports on ZFGN shares. Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research note on Saturday, August 12th. ValuEngine upgraded Zafgen from a “strong sell” rating to a “sell” rating in a report on Monday, October 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $6.63.

In related news, Director Frances K. Heller acquired 10,000 shares of the firm’s stock in a transaction dated Friday, October 13th. The stock was acquired at an average price of $3.90 per share, for a total transaction of $39,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 21.20% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in ZFGN. Algert Global LLC purchased a new position in shares of Zafgen in the 2nd quarter valued at about $123,000. Parametric Portfolio Associates LLC raised its position in shares of Zafgen by 55.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock worth $134,000 after acquiring an additional 10,327 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Zafgen during the 2nd quarter worth about $259,000. LMR Partners LLP acquired a new stake in shares of Zafgen during the 2nd quarter worth about $299,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Zafgen during the 2nd quarter worth about $304,000. Institutional investors and hedge funds own 48.57% of the company’s stock.

Shares of Zafgen (NASDAQ ZFGN) traded down $0.07 on Friday, hitting $3.65. The company’s stock had a trading volume of 64,300 shares, compared to its average volume of 201,749. Zafgen has a twelve month low of $3.11 and a twelve month high of $5.46.

ILLEGAL ACTIVITY NOTICE: “Zafgen, Inc. (ZFGN) Expected to Announce Earnings of -$0.59 Per Share” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.watchlistnews.com/zafgen-inc-zfgn-expected-to-announce-earnings-of-0-59-per-share/1724282.html.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Get a free copy of the Zacks research report on Zafgen (ZFGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.